Investment Rating - The report maintains a HOLD rating for China Tower, with a target price adjusted to HK$12.10 from the previous HK$13.10, indicating a potential upside of 13.2% from the current price of HK$10.69 [1][2]. Core Insights - China Tower's FY25 revenue increased by 2.7% YoY to RMB100.4 billion, aligning closely with estimates, while net profit rose 8.4% YoY to RMB11.6 billion, slightly above estimates [1]. - The improvement in net margin by 0.6 percentage points to 11.6% was primarily due to a lower depreciation and amortization (D&A) expense ratio [1]. - The tower business faced pressure with a 0.3% YoY decline in tower revenue, which constitutes 75% of total sales, as domestic telco capital expenditures (capex) decreased by 10.5% YoY [6]. - The report forecasts a continued decline in tower revenue by 1.5% YoY in 2026, reflecting flat site counts and ongoing pricing pressure [6]. - The DAS and Two Wings segments showed solid growth, with DAS revenue growing 9.5% YoY and Smart Tower revenue increasing 14.2% YoY [6]. - The company declared a full-year dividend per share (DPS) of RMB0.458, representing a 9.8% YoY increase, with a payout ratio of 77% [1]. Financial Summary - FY25 revenue was RMB100.4 billion, with projected revenues of RMB102.1 billion for FY26 and RMB103.3 billion for FY27, indicating a slowdown in growth [7]. - Net profit for FY25 was RMB11.6 billion, with projections of RMB15.4 billion for FY26 and RMB15.7 billion for FY27, reflecting a significant growth rate of 32.1% in FY26 [7]. - The EBITDA margin is expected to decline to 61.2% in FY26, down from 65.5% in FY25, indicating rising operational costs [8]. - The company’s total liabilities are projected to decrease from RMB132.7 billion in FY25 to RMB113.3 billion in FY26, improving the overall financial health [15].

Investment Rating - The report maintains a "Buy" rating for China Biopharmaceutical (1177 HK) [7] Core Views - The company reported a revenue growth of 10.3% year-on-year to RMB 31.83 billion for FY25, with innovative product revenue increasing by 26.2% to RMB 15.2 billion, accounting for 47.8% of total revenue [1] - Adjusted net profit grew by 31.4% year-on-year to RMB 4.54 billion, and if excluding dividends from Sinovac, the adjusted net profit still increased by 15% [1] - The company’s FY25 revenue was below expectations by 7.4% compared to the report's forecast and 3.9% compared to Bloomberg consensus, while adjusted net profit fell short by 27.5% and 9.0% respectively, mainly due to a milestone payment from Merck not being recognized as expected [1] - The company is expected to continue steady growth in FY26, driven by stable generic drug revenue and ongoing sales momentum from innovative drugs [1] Financial Summary - FY24A revenue is projected at RMB 28.87 billion, with a year-on-year growth of 10.2% - FY25A revenue is projected at RMB 31.83 billion, with a year-on-year growth of 10.3% - FY26E revenue is projected at RMB 36.13 billion, with a year-on-year growth of 13.5% [2] - Adjusted net profit for FY26E is expected to be RMB 4.79 billion, reflecting a year-on-year growth of 5.4% [2] - The adjusted earnings per share for FY26E is projected at RMB 0.26 [2] Target Price and Market Performance - The target price is set at HKD 8.70, down from the previous target of HKD 9.40, indicating a potential upside of 47.7% from the current price of HKD 5.89 [3] - The market capitalization is approximately HKD 110.5 billion [3] Shareholder Structure - The major shareholders include Xie Chengrun with 21.6% and Zheng Xiangling with 15.8% [4] Price Performance - The stock has shown a 1-month absolute return of -2.6% and a 3-month return of -8.3% [5]

Investment Rating - The investment rating for Tianhong International Group is "Buy" [2][3]. Core Views - The gross margin for the yarn business improved by 2.5 percentage points to 14.2% in 2025, driven by debt repayment which significantly reduced financial expenses [3][6]. - Yarn sales are expected to grow by 1.4% in 2026, benefiting from rising cotton prices, thus maintaining the "Buy" rating [3][6]. - The company plans to increase yarn production capacity in Vietnam by 100,000 spindles, raising total capacity to 4.35 million spindles, a 2.4% year-on-year increase [6]. Financial Summary - Total revenue for 2025 is projected at 22,716 million RMB, a decrease of 1.4% year-on-year, while net profit attributable to shareholders is expected to reach 913 million RMB, a 64.9% increase [5][6]. - The gross profit for 2025 is estimated at 3,138 million RMB, with a gross margin of 14.2% [5][6]. - The company’s financial expenses for 2025 are expected to be 1.7 billion RMB, down by 2.2 billion RMB year-on-year, resulting in a financial expense ratio of 0.7% [6][8]. Profit Forecast - The forecast for net profit attributable to shareholders for 2026, 2027, and 2028 is 1,088 million RMB, 1,192 million RMB, and 1,284 million RMB respectively [5][6]. - The projected PE ratio for 2026 is 8x, with a target price of 10.77 HKD based on a conversion rate of 1 HKD = 0.88 RMB [6][8]. Market Position - Tianhong International Group's current market capitalization is 5,719 million HKD, with a share price of 6.23 HKD [2][6]. - The company is positioned as a leading player in the global yarn market, entering a phase of profitability growth [6].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 4.20 [1][9]. Core Views - The report highlights a recovery in the large-volume infusion and ampoule segments over the next 26 years, with high growth expected in oral formulations and an accelerated innovation transformation [1][5]. - The company reported a revenue of HKD 4.165 billion for 2025, a decrease of 27.8% year-on-year, and a net profit of HKD 470 million, down 55.6% year-on-year, which aligns with previous performance forecasts [1][5]. - The decline in revenue and profit is attributed to the increased proportion of products subject to volume-based procurement, a drop in unit prices for basic infusions and ampoules, and weak demand for raw materials [5][6]. Summary by Sections Financial Performance - For 2025, the company’s revenue is projected at HKD 4.165 billion, with a year-on-year decline of 27.85%. The net profit is expected to be HKD 470 million, reflecting a 55.65% decrease [4][5]. - The earnings per share (EPS) for 2025 is estimated at HKD 0.16, with projections for 2026, 2027, and 2028 at HKD 0.20, HKD 0.26, and HKD 0.32 respectively [4][9]. Segment Analysis - **Large-volume Infusions**: Revenue for 2025 is expected to be HKD 2.49 billion, down 33.5% year-on-year, primarily due to decreased sales volume and average selling price (ASP) [6]. - **Raw Materials**: The raw material segment is projected to generate HKD 680 million in 2025, a decline of 14% year-on-year, with expectations for recovery in 2026 driven by improved demand and pricing [7]. - **Oral Formulations**: Revenue for oral formulations is expected to be HKD 455 million in 2025, with a 15% increase in sales volume, driven by new product approvals [8]. Future Outlook - The report anticipates a recovery in 2026, with profit growth potentially reaching nearly 30%, supported by structural optimization in large-volume infusions, increased export ratios for formulations and raw materials, and a rebound in prices [5][6][8]. - The company is actively advancing its innovation pipeline, with a focus on new drug development, including several promising candidates in clinical trials [8].

Investment Rating - The investment rating for Anta Sports (02020.HK) is "Buy" (maintained) [1] Core Views - The report highlights that Anta Sports achieved a revenue of 80.22 billion yuan in 2025, representing a year-on-year growth of 13.3%. However, the net profit attributable to shareholders decreased by 12.9% to 13.59 billion yuan. Excluding the impact of the previous year's Amer Sports listing and dilution, the net profit increased by 13.9% year-on-year [8] - The multi-brand strategy is expected to sustain growth, with significant contributions from the outdoor segment and the successful performance of various brands under the Anta umbrella [8] Financial Summary - **Revenue Forecasts**: - 2024A: 70.83 billion yuan - 2025A: 80.22 billion yuan - 2026E: 88.61 billion yuan - 2027E: 97.49 billion yuan - 2028E: 107.14 billion yuan - Year-on-year growth rates are projected at 13.58% for 2024, 13.26% for 2025, and gradually decreasing thereafter [1][9] - **Net Profit Forecasts**: - 2024A: 15.60 billion yuan - 2025A: 13.59 billion yuan - 2026E: 15.60 billion yuan - 2027E: 15.71 billion yuan - 2028E: 17.48 billion yuan - The net profit growth rate shows a significant increase of 52.36% in 2024, followed by a decrease of 12.88% in 2025, and a recovery in subsequent years [1][9] - **Earnings Per Share (EPS)**: - 2024A: 5.58 yuan - 2025A: 4.86 yuan - 2026E: 5.58 yuan - 2027E: 5.62 yuan - 2028E: 6.25 yuan [1] - **Price-to-Earnings (P/E) Ratio**: - 2024A: 11.93 - 2025A: 13.69 - 2026E: 11.93 - 2027E: 11.84 - 2028E: 10.64 [1] Brand Performance - **Anta Brand**: Revenue reached 34.75 billion yuan in 2025, with a year-on-year growth of 3.7%. The direct-to-consumer (DTC) segment showed a growth of 5.9% [8] - **FILA**: Revenue increased to 28.47 billion yuan, with a year-on-year growth of 6.9%. The brand's focus on high-end sports fashion is enhancing its competitiveness [8] - **Other Brands**: Revenue from other brands reached 17.00 billion yuan, with a significant year-on-year growth of 59.2%. DESCENTE's revenue surpassed 10 billion yuan [8]

Investment Rating - The report maintains an "Outperform" rating for Mao Geping Cosmetics [2][3]. Core Insights - The company achieved a revenue of RMB 5.05 billion in 2025, reflecting a year-on-year growth of 30%, and net profit attributable to the parent was RMB 1.20 billion, up 36.7% year-on-year [4][12]. - Management has set a growth guidance of 30% for the upcoming years, with expectations for revenue to reach RMB 6.50 billion, RMB 8.15 billion, and RMB 9.97 billion in 2026, 2027, and 2028, respectively [3][11]. - The company’s net profit margins are projected to remain robust at 23.3%, 22.9%, and 22.7% for the years 2026 to 2028 [11]. Financial Performance - Revenue for 2025 was RMB 5.05 billion, slightly below expectations by 1.0%, while net profit exceeded expectations by 0.2% [4][12]. - The gross profit margin for 2025 was reported at 84.2%, which is an improvement of 0.3 percentage points compared to expectations [8]. - The company’s diluted EPS for 2025 was RMB 2.46, with a projected increase to RMB 3.09 in 2026 [2][10]. Product Performance - Key products such as the Luxury Caviar Cushion and the Luxury Caviar Mask have shown strong sales, contributing significantly to revenue [5][13]. - The color cosmetics segment generated RMB 3.00 billion in revenue for 2025, while skincare revenue reached RMB 1.87 billion, both showing substantial year-on-year growth [14][15]. - New product launches in 2026 are expected to further enhance sales, particularly in the skincare and eye makeup categories [5][13]. Market Position and Strategy - The company has successfully increased its online sales, which accounted for over 50% of total revenue for the first time, with a year-on-year growth of 38.8% [6][15]. - Offline same-store sales grew by 16%, indicating strong brand loyalty and customer retention [6][15]. - Mao Geping Cosmetics aims to continue expanding its high-end market presence while maintaining a clear strategy focused on online customer acquisition and premium product offerings [14][15].

Investment Rating - The report maintains a "Buy" investment rating for Bilibili-W (9626.HK) [2] Core Insights - Bilibili's commercial value is expected to enhance in the AI era, with a focus on improving its monetization capabilities [5][6] - The company is projected to achieve a revenue of 30.348 billion yuan in 2025, with a year-on-year growth of 13.1%, and a net profit of 1.194 billion yuan, marking a return to profitability [5] - The user base is growing, with daily active users reaching 113 million and monthly active users at 366 million by Q4 2025, indicating strong user engagement [5] - Bilibili's advertising business is anticipated to benefit from the attention economy driven by AI, with significant growth potential in brand, performance, and native advertising [6] - The company plans to increase its investment in AI to enhance content understanding and promote AI-assisted creation tools for content creators [7] Financial Projections - Revenue forecasts for 2026-2028 are 32.243 billion yuan, 35.319 billion yuan, and 38.248 billion yuan respectively, with corresponding net profits of 1.802 billion yuan, 2.708 billion yuan, and 3.503 billion yuan [8] - The earnings per share (EPS) are projected to be 4.28 yuan, 6.43 yuan, and 8.32 yuan for 2026, 2027, and 2028 respectively, with price-to-earnings (P/E) ratios of 45, 30, and 23 [8]

Investment Rating - The report maintains an "Outperform" rating for Mao Geping Cosmetics [2][3]. Core Insights - The company achieved a revenue of RMB 5.05 billion in 2025, reflecting a year-on-year growth of 30%, and net profit attributable to the parent was RMB 1.20 billion, up 36.7% year-on-year [4][12]. - Management has set a growth guidance of 30% for the upcoming years, with expectations for revenue to reach RMB 6.50 billion, RMB 8.15 billion, and RMB 9.97 billion in 2026, 2027, and 2028, respectively [3][11]. - The company has demonstrated strong performance in its core product lines, with significant contributions from new product launches in both color cosmetics and skincare [5][13]. Financial Performance - For 2025, the company reported a gross profit margin of 84.2% and a net profit margin of 23.8% [4][12]. - The projected net profit for 2026 is RMB 1.52 billion, with a net profit margin of 23.3%, and is expected to grow at a rate of 25.8% year-on-year [3][11]. - The company’s revenue growth is expected to slow slightly to 28.7% in 2026, 25.4% in 2027, and 22.4% in 2028 [3][11]. Product Performance - Key products such as the Luxury Caviar Cushion and the Luxury Caviar Mask have shown strong sales, contributing significantly to the overall revenue [5][13]. - The color cosmetics segment generated RMB 3.00 billion in revenue for 2025, while skincare revenue reached RMB 1.87 billion, indicating robust growth in both categories [14][15]. Market Position and Strategy - The company has successfully increased its online sales, which accounted for over 50% of total revenue for the first time, with a year-on-year growth of 38.8% [6][15]. - Mao Geping Cosmetics plans to continue expanding its high-end product lines and enhance its online presence to attract more customers [5][14].

Investment Rating - The report maintains an "Outperform" rating for Haidilao International Holding [2][3]. Core Insights - Haidilao's revenue is projected to reach RMB 45.06 billion in 2026, with a year-on-year growth of 4.2%. Net profit is expected to be RMB 4.36 billion, reflecting a growth of 7.7% [3][13]. - The flagship brand's operational performance stabilized in the second half of 2025, with a slight increase in average spend per guest, while the table turnover rate showed a modest recovery [4][14]. - The "Pomegranate Plan" has successfully transitioned from internal incubation to market validation, with significant revenue contributions from new sub-brands [5][15]. - The delivery business has shown strong growth, becoming a key revenue pillar, with a full-year revenue of RMB 2.66 billion, up 111.9% year-on-year [6][16]. Financial Projections - Revenue and net profit forecasts for Haidilao from 2026 to 2028 are as follows: - 2026: Revenue of RMB 45.06 billion, net profit of RMB 4.36 billion - 2027: Revenue of RMB 47.41 billion, net profit of RMB 4.90 billion - 2028: Revenue of RMB 50.47 billion, net profit of RMB 5.44 billion [3][10][13]. - The gross profit margin is expected to remain stable around 59% for the forecast period [10][12]. Operational Performance - The main brand's revenue for 2025 was RMB 37.54 billion, a decrease of 7.1% year-on-year, with a table turnover rate of 3.9 times per day [4][14]. - The company operated 1,383 restaurants by the end of 2025, with a net addition of 15 locations during the year [4][14]. Strategic Developments - Zhang Yong's return as CEO aims to enhance strategic execution and organizational efficiency, particularly in expanding the multi-brand strategy under the Pomegranate Plan [8][17]. - The company plans to increase capital expenditure on new business initiatives in 2026, which may impact short-term profitability but is expected to drive long-term growth [5][19].

Investment Rating - The report upgrades the investment rating to "Buy" [7] Core Views - The company's 2025 annual report shows revenue of HKD 6.87 billion, down 20.3% year-on-year, while net profit attributable to shareholders is HKD 0.453 billion, up 32.4% year-on-year, exceeding expectations due to recovery from prior losses [2] - The company has a stable supply capacity from quality overseas mines and is expected to benefit from the upward cycle of uranium prices, making it one of the most elastic uranium mining stocks [2][4] - The new three-year sales framework agreement is expected to enhance revenue stability and profit elasticity, with a significant increase in the fixed price component [4][5] Financial Performance - The company produced 2,699 tons of uranium in 2025, a decrease of 2% year-on-year, with sales costs rising to USD 29 per pound, an 11% increase due to higher taxes and material costs [3] - The sales framework for 2026-2028 includes a significant increase in the base price for uranium, which is expected to enhance the company's revenue base [4] - The forecast for net profit attributable to shareholders for 2026-2028 is HKD 1.041 billion, HKD 1.337 billion, and HKD 1.570 billion respectively, with corresponding EPS of HKD 0.14, HKD 0.18, and HKD 0.21 [6][11] Market Outlook - The report emphasizes that the natural uranium market is entering a dual resonance phase driven by nuclear power revival and strategic stockpiling, which is expected to lead to higher uranium prices [5] - The company is positioned to benefit from the expected increase in uranium prices due to a shift from inventory depletion to replenishment [5]